Riskpilot← Back to searchSign inGet full accessAmgen Aktiebolag
ABActiveOrg 5565104212Berzelius Väg 35Research and experimental development on natural sciences and engineering · NACE 7210Est. 1995189 employees
Revenue 2024
SEK 2,8B
+19% vs 2023
EBITDA margin
4.3%
+25% vs 2023
Equity ratio
30.3%
Financial strength
Net profit 2024
SEK 96,2M
+25% vs 2023
| Revenue | SEK 2,8B | +19% |
| EBITDA | SEK 118,8M | +25% |
| Net profit | SEK 96,2M | +25% |
| Total assets | SEK 1,4B | +28% |
| Equity | SEK 424,5M | +29% |
| Employees | 189 | — |
Legal name
Amgen Aktiebolag
Org number
5565104212
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
19 april 1995
Share capital
SEK 3 000 000
Employees
189 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna Firman tecknas i förening av externa firmatecknarna
Company purpose
Bolagets verksamhet skall vara distribution, försäljning, konsultation och marknadsföring ävensom klinisk forskning av och inom alla slag av farmaceutiska produkter och teknisk medicinsk utrustning samt idka därmed förenlig verksamhet.
Address
Berzelius Väg 35
Phone
+4686951100
Email
sinsakov@amgen.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 1 708 627 | 1 823 789 | 2 073 806 | 2 339 680 | 2 783 154 |
| Staff expenses | — | — | −306 007 | — | −338 582 |
| EBITDA | 70 118 | 84 037 | 97 348 | 94 665 | 118 751 |
| Depreciation & amort. | −2 946 | −3 617 | −4 314 | −3 772 | −3 411 |
| EBIT | 67 172 | 80 420 | 93 034 | 90 893 | 115 340 |
| Net financials | −964 | −297 | 1 442 | 14 163 | 20 768 |
| Profit before tax | 66 663 | 80 338 | 94 476 | 105 171 | 136 108 |
| Tax | −14 937 | −21 207 | −25 029 | −28 036 | −39 931 |
| Net profit | 51 726 | 59 131 | 69 447 | 77 135 | 96 177 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 681 151 | 740 749 | 853 489 | 1 092 526 | 1 402 528 |
| Equity | 123 186 | 182 317 | 251 763 | 328 298 | 424 476 |
| Long-term debt | 0 | 0 | — | 0 | — |
| Short-term debt | 553 482 | 552 861 | 599 238 | 759 745 | 973 570 |
| Total debt | 553 482 | 552 861 | 599 238 | 759 745 | 973 570 |
EBITDA margin
4.3%
This company
15.8%
Market median
-73% vs market
20202024
Equity ratio
30.3%
This company
38.2%
Market median
+21% vs market
20202024
Return on equity
22.7%
This company
18.4%
Market median
+23% vs market
20202024
Net profit margin
3.5%
This company
8.1%
Market median
-57% vs market
20202024
Asset turnover
1.98×
This company
1.12×
Market median
+77% vs market
20202024
Debt / equity
2.30×
This company
0.62×
Market median
-271% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
TG External Signatory | External Signatory | 2024 |
EJ External Signatory | External Signatory | 2020 |
ME Chief Auditor | Chief Auditor | 2022 |
| Former (5) | ||
MT External Signatory | External Signatory | 2020 – 2022 |
IM Chief Auditor | Chief Auditor | 2022 – 2024 |
TL External Signatory | External Signatory | 2022 – 2024 |
JE Chief Auditor | Chief Auditor | 2020 – 2022 |
CH External Signatory | External Signatory | 2020 – 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2023 | |
| Board of Directors | 2021 | |
| Chairman | 2020 | |
| Former (3) | ||
| Board of Directors | 2020 – 2021 | |
| Board of Directors | 2021 – 2023 | |
| Board of Directors | 2020 – 2021 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
AMGEN WORLDWIDE HOLDINGS B.V
Amgen Aktiebolag (this company)Board members of Amgen Aktiebolag also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Thomas Gilles Philippe Lavaud | External Signatory | 0 companies |
| Eleonore Judith Hassila | External Signatory | 0 companies |
| Marcin Tuz | External Signatory | 0 companies |
| Maria Erzsébet Magdalena Lennmark | Chief Auditor | 0 companies |
| Ida Maria Brandt | Chief Auditor | 0 companies |
| Thomas Lavaud | External Signatory | 0 companies |
| Johan Erik Sylvén | Chief Auditor | 0 companies |
| Carl Henrik Victor Bergqvist | External Signatory | 0 companies |
| Justin Gary Claeys | Board of Directors | 0 companies |
| Paraskevi Florou | Board of Directors | 0 companies |
| Sandra Elisabeth Eketorp Sylvan | Board of Directors | 0 companies |
| Adam Stewart Elinoff | Board of Directors | 0 companies |
| Harriet Annika Olsson | Board of Directors | 0 companies |
| Karin Louise Ulrika Järperud | Chairman | 0 companies |